Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - NeuBase Therapeutics, Inc. | ex-99_1.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2012
Ohr Pharmaceutical,
Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 333-88480 | #90-0577933 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 489 5th Ave, 28th Floor, New York, NY | 10017 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212)-682-8452
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Items.
On May 14, 2012, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to the Squalamine eye drop program for the treatment of the wet form of macular degeneration (wet-AMD).
A copy of the press release is attached to this Current Report on Form 8-K as exhibit 99.1.
| Exhibit No. | Description | |
|---|---|---|
| 99.1 | Press Release Announcing U.S. FDA Fast Track Designation, dated May 14, 2012 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| OHR PHARMACEUTICAL, INC. | ||
| By: | /s/ Irach Taraporewala | |
| Dr. Irach Taraporewala, President and CEO | ||
Date: May 14, 2012